Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update

Completed acquisition of Trawsfynydd and concurrent $14 million Capital Raise Excellent pipeline progress, led by candidates for COVID 19, influenza, and oncology programs Poised to initiate Phase 2...

Related Keywords

Australia ,Traws Pharma ,Mark Guerin ,Bruce Mackle ,Werner Cautreels ,Torrey Pines ,Securities Exchange ,Exchange Commission ,Lifesci Advisors ,Traws Pharma Inc ,Chief Executive Officer ,Proprietary Portfolio Highlights ,Orbimed Private Investments ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Sci Advisors ,Consolidated Statements ,Months Ended March ,